# HERVolution Therapeutics

> HERVolution Therapeutics is a Copenhagen-based biotechnology company developing immunotherapies that target human endogenous retroviruses (HERVs) - dormant remnants of ancient viruses embedded in human DNA that can reactivate with age and disease. Formerly named InProTher, the company has engineered a proprietary platform that redesigns these 'dark genome' antigens to break immune tolerance, making them visible to the immune system for the first time. Its off-the-shelf vector-based pipeline, led by IPT-001, aims to treat cancer, metabolic disease, and other diseases of aging.

- **Headquarters:** Frederiksberg (Copenhagen), Denmark
- **Founders:** Peter Holst (Founder & Chief Scientific Officer)
- **Team size:** ~36 employees
- **Products:** IPT-001, IPT-002, Dark genome / HERV engineering platform
- **Notable:** Demonstrated human immune cell activation toward HERVs for the first time, per the company., Raised an $11.7M Series A led by the Serum Institute of India with EIC Fund participation (Dec 2024)., Recruited biotech builder J. Robert Coleman (Codagenix co-founder) as CEO in Dec 2023.

## Products & services

- **IPT-001** — Lead program: a dual adenoviral vector immune therapy designed to induce potent HERV-specific T and B cell responses, as monotherapy or in combination. Being advanced toward first-in-human studies in oncology and metabolic disease, in development with the Serum Institute of India.
- **IPT-002** — An mRNA vector expressing a proprietary HERV antigen, enabling repeat dosing and maintenance of anti-HERV immune responses in prime-boost strategies alongside IPT-001.
- **Dark genome / HERV engineering platform** — A proprietary protein-engineering platform that rationally redesigns HERV antigens to break immune tolerance, making dormant 'self' antigens recognizable to the human immune system.

## Achievements

- Demonstrated human immune cell activation toward HERVs for the first time, per the company.
- Raised an $11.7M Series A led by the Serum Institute of India with EIC Fund participation (Dec 2024).
- Recruited biotech builder J. Robert Coleman (Codagenix co-founder) as CEO in Dec 2023.
- Signed an exclusive license with the University of Copenhagen for HERV weight-control technology (2026).
- Presented clinical evidence linking HERV-K reactivation to metabolic senescence at the International Congress on Obesity 2026.
- Built an off-the-shelf pipeline (IPT-001 adenoviral, IPT-002 mRNA) spanning oncology and metabolic disease.

## Latest updates

- **2026-07** — Presented clinical evidence that HERV-K drives metabolic senescence at the International Congress on Obesity 2026 (Mexico City, July 15-17).
- **2026-06** — Reported preclinical proof-of-concept for an insulin-sensitization immune therapy and announced an exclusive HERV weight-control license with the University of Copenhagen.
- **2024-12** — Closed an $11.7M Series A led by the Serum Institute of India to advance IPT-001 and IPT-002 toward the clinic.
- **2023-12** — Appointed J. Robert Coleman as CEO to accelerate its dark genome immunotherapy programs.

## Links

- Website: https://hervolutiontx.com
- LinkedIn: https://www.linkedin.com/company/hervolutiontx/
- Twitter/X: https://twitter.com/Hervolutiontx

---

Profile page: https://yespress.io/hervolution-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-07-20